Micrometastasis to lymph nodes in stage I left lung cancer patients

被引:35
|
作者
Kawano, R [1 ]
Hata, E [1 ]
Ikeda, S [1 ]
Sakaguchi, H [1 ]
机构
[1] Mitsui Mem Hosp, Resp Ctr, Dept Surg, Chiyoda Ku, Tokyo, Japan
来源
ANNALS OF THORACIC SURGERY | 2002年 / 73卷 / 05期
关键词
D O I
10.1016/S0003-4975(02)03398-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. To evaluate the frequency and clinicopathological characteristics of lymph node micrometastasis in left lung cancer patients diagnosed to be stage IA and IB based on routine histopathologic examinations, we examined the lymph nodes in patients who had undergone an extended mediastinal lymphadenectomy, using immunohistochemical methods. Methods. Paraffin-embedded tissue sections from the lymph nodes in 49 patients with stage I left lung cancers were studied. We used AE1/AE3 as the anticytokeratin and Ber-EP4 as the antiepithelial cell antibodies when performing immunohistochemical staining. Results. We identified micrometastasis of the lymph nodes in 13 (26.5%) of 49 patients with stage I left lung cancer. NO disease was reclassified as N1 disease in 5 cases, N2 disease in 6 cases, and N3 disease in 2 cases. The location of the micrometastatic lymph nodes proved to be wide regions including the contralateral and highest mediastinal nodes, and 6 (46.2%) out of the 13 patients with micrometastasis were thus presumed not to be completely eliminated by a standard lymphadenectomy through an ipsilateral thoracotomy. The five year survival rate of patients with reclassified NI to N3 disease was 74%, and the presence of micrometastasis was found to have no significant effect oil the outcomes. Conclusions. The micrometastatic involvement of the lymph nodes was both more frequent and extensive than expected even in stage I left lung cancer. These results suggest that an extended mediastinal lymphadenectomy may therefore be required for the locoregional control of stage I left lung cancer patients.
引用
收藏
页码:1558 / 1562
页数:5
相关论文
共 50 条
  • [1] Micrometastasis to lymph nodes in stage I left lung cancer patients - Invited commentary
    Ginsberg, RJ
    ANNALS OF THORACIC SURGERY, 2002, 73 (05): : 1562 - 1562
  • [2] Relationship between micropapillary component and micrometastasis in the regional lymph nodes of patients with stage I lung adenocarcinoma
    Roh, MS
    Lee, JI
    Choi, PJ
    Hong, YS
    HISTOPATHOLOGY, 2004, 45 (06) : 580 - 586
  • [3] Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients
    Harden, SV
    Tokumaru, Y
    Westra, WH
    Goodman, S
    Ahrendt, SA
    Yang, SC
    Sidransky, D
    CLINICAL CANCER RESEARCH, 2003, 9 (04) : 1370 - 1375
  • [4] Micrometastasis in lymph nodes of colorectal cancer
    Yamamoto, Hirofumi
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2022, 6 (04): : 466 - 473
  • [5] Regulatory T-Cells and Micrometastasis in Lymph Nodes of Stage I NSCLC
    Hanagiri, Takeshi
    Fukumoto, Misako
    Koyanagi, Yukiko
    Furutani, Yukari
    Tanaka, Fumihiro
    ANTICANCER RESEARCH, 2014, 34 (12) : 7185 - 7190
  • [6] Predicting Micrometastasis in Mediastinal Lymph Nodes in Patients with Non-Small Cell Lung Cancer
    Erus, S.
    Suer, H.
    Kapdagli, M.
    Tanju, S.
    Dilege, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S828 - S828
  • [7] Micrometastasis in lymph nodes of mucosal gastric cancer
    Cai J.
    Ikeguchi M.
    Tsujitani S.
    Maeta M.
    Kaibara N.
    Gastric Cancer, 2000, 3 (2) : 91 - 96
  • [8] Assessment of lymph nodes for micrometastasis in high risk patients with colorectal cancer
    Botiralieva, G.
    Nishanov, D.
    Navruzov, S.
    ANNALS OF ONCOLOGY, 2016, 27 : 8 - 8
  • [9] Micrometastasis to axillary lymph nodes and bone marrow in breast cancer patients
    Wiedswang, G
    Næss, AB
    Naume, B
    Kåresen, R
    BREAST, 2001, 10 (03): : 237 - 242
  • [10] The clinical significance of lymph node micrometastasis in stage I and stage II colorectal cancer
    Mark Davies
    Ponnandai J. Arumugam
    Varsha I. Shah
    Alun Watkins
    Andrew Roger Morgan
    Nicholas D. Carr
    John Beynon
    Clinical and Translational Oncology, 2008, 10 : 175 - 179